Published • loading... • Updated
HLA Protein Technologies’ New NCI License Speeds TCR Immunotherapy and Oncology Discovery
The internal-use license gives HLA Protein Technologies access to engineered T-cell receptor cell lines and HLA tools to speed immunotherapy development.
- On Tuesday, HLA Protein Technologies secured an internal use license from the National Cancer Institute , covering advanced T-cell receptor compositions and research methods for immunotherapy and oncology research.
- Formerly known as Pure Protein, LLC, HLA Protein Technologies provides soluble, natively folded recombinant HLA proteins with more than 25 years of expertise supporting research across over 20 countries.
- Chief Scientific Officer Rico Buchli said the license reflects the firm's commitment to "delivering best-in-class HLA and tetramer products," helping biopharma accelerate next-generation immunotherapy development for cancer.
- Under the license, the company gains access to cell lines engineered to express clinically relevant T-cell receptors, driving portfolio expansion and manufacturing activities at its Oklahoma City headquarters.
- Director Michelle Gregory of Life Science Oklahoma stated the license "underscores the innovative spirit of Oklahoma's life sciences sector," aligning with efforts to expand USA-based life sciences manufacturing.
Insights by Ground AI
14 Articles
14 Articles
Le Journal de MontrealReposted by 
Le Journal de Quebec
Le Journal de QuebecThis method helps the immune system recognize and attack cancer cells.
·Montreal, Canada
Read Full Article
HLA Protein Technologies' New NCI License Speeds TCR Immunotherapy and Oncology Discovery
OKLAHOMA CITY, Okla., Aug. 11, 2026 (SEND2PRESS NEWSWIRE) -- HLA Protein Technologies, Inc. (formerly Pure Protein, LLC), a global leader in soluble, natively folded HLA proteins and custom peptide binding services, announced a major step forward for TCR research. The Company has secured an internal use license from the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), covering advanced T-cell receptor (TCR…
·United States
Read Full ArticleCoverage Details
Total News Sources14
Leaning Left4Leaning Right1Center7Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 33%
C 59%
Factuality
To view factuality data please Upgrade to Premium
